Gitlin N - Search Results

1

Misoprostol in the treatment of duodenal ulcer refractory to H2-blocker therapy. A placebo-controlled, multicenter, double-blind, randomized trial.

Newman RD, Gitlin N, Lacayo EJ, Safdi AV, Ramsey EJ, Engel SL, Rubin A, Nissen CH, Swabb EA. Newman RD, et al. Among authors: gitlin n. Am J Med. 1987 Jul 27;83(1A):27-31. doi: 10.1016/0002-9343(87)90575-4. Am J Med. 1987. PMID: 2887112 Clinical Trial.

2

A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease.

Gitlin N, McCullough AJ, Smith JL, Mantell G, Berman R. Gitlin N, et al. Gastroenterology. 1987 Jan;92(1):48-53. doi: 10.1016/0016-5085(87)90838-9. Gastroenterology. 1987. PMID: 2877912 Clinical Trial.

3

Omeprazole versus placebo in duodenal ulcer healing. The United States experience.

Graham DY, McCullough A, Sklar M, Sontag SJ, Roufail WM, Stone RC, Bishop RH, Gitlin N, Cagliola AJ, Berman RS, et al. Graham DY, et al. Among authors: gitlin n. Dig Dis Sci. 1990 Jan;35(1):66-72. doi: 10.1007/BF01537225. Dig Dis Sci. 1990. PMID: 2403908 Clinical Trial.

4

Famotidine once-a-day in the management of duodenal ulcer: the U.S. placebo-controlled experience.

Gitlin N. Gitlin N. J Clin Gastroenterol. 1987;9 Suppl 2:13. doi: 10.1097/00004836-198707002-00004. J Clin Gastroenterol. 1987. PMID: 3624832 Clinical Trial. No abstract available.

5

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-2/3 Study Team. Nelson DR, et al. Gastroenterology. 2010 Oct;139(4):1267-76. doi: 10.1053/j.gastro.2010.06.062. Epub 2010 Jul 1. Gastroenterology. 2010. PMID: 20600017 Free PMC article. Clinical Trial.

6

Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.

McHutchison JG, Patel K, Schiff ER, Gitlin N, Mur RE, Everson GT, Carithers RL Jr, Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK; International Hepatitis Interventional Therapy Group. McHutchison JG, et al. Among authors: gitlin n. Aliment Pharmacol Ther. 2008 Mar 1;27(5):422-32. doi: 10.1111/j.1365-2036.2007.03590.x. Epub 2007 Dec 11. Aliment Pharmacol Ther. 2008. PMID: 18081733 Free article. Clinical Trial.

7

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Foster GR, et al. N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17. N Engl J Med. 2015. PMID: 26575258 Free article. Clinical Trial.

8

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N. Dienstag JL, et al. Among authors: gitlin n. Hepatology. 1999 Oct;30(4):1082-7. doi: 10.1002/hep.510300427. Hepatology. 1999. PMID: 10498663

9

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.

Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M; REEF-1 Study Group. Yuen MF, et al. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37442152 Clinical Trial.

10

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.

Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Barritt AS, et al. Among authors: gitlin n. Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun. Hepatol Commun. 2021. PMID: 34141981 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

98 results

Search Page